Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | S-531011 + unspecified PD-1 antibody |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| S-531011 | S 531011|S531011 | CCR8 Antibody 13 | S-531011 is an antibody that targets CCR8, potentially resulting in antibody-dependent cellular cytotoxicity against regulatory T-cells expressing CCR8 and inhibition of tumor growth (Journal for ImmunoTherapy of Cancer 2021;9). | |
| unspecified PD-1 antibody | Experimental PD-1 antibody | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 132 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|